Janux Therapeutics enters into $150M ATM equity offering agreement with BofA

Janux Therapeutics, Inc.

Up to $150M in common stock may be sold at the company's discretion through BofA as sales agent or principal.
BofA will receive up to 3% commission on gross proceeds; company also reimburses certain legal fees.
Sales may occur via negotiated transactions, block trades, or at-the-market on Nasdaq.
The offering is under an existing S-3 registration statement; no obligation to sell any shares.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Janux Therapeutics, Inc. entered into ATM Equity Offering Sales Agreement with BofA Securities, Inc. valued at up to $150.0 million (effective 2023-05-09).

Action: entry
Agreement: atm program
Counterparty: BofA Securities, Inc.
Value: up to $150.0 million
Effective: 2023-05-09

Exact text from the filing

On May 9, 2023, Janux Therapeutics, Inc. (the “Company”) entered into an ATM Equity OfferingSM Sales Agreement (the “Agreement”) with BofA Securities, Inc. (“BofA”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $150.0 million

View on SEC.gov

Browse all material agreements →

Janux Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-019856

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.